It's important to acknowledge that these are common, with studies indicating that a significant percentage of users (reports range from 40% up to 85%) experience issues like nausea, vomiting, diarrhea, constipation, bloating, or heartburn, particularly when first starting the medication or increasing the dose
SURMOUNT OSA demonstrated after 52 weeks of treatment, participants who received tirzepatide had greater likelihood of remission or improvement to mild OSA as well as reduced apnea-hypopnea index (AHI) values, hypoxic burden, and systolic blood pressure
What to Expect When Starting Microdosing GLP-1 Beginning any injectable medication can feel intimidating, but microdosing GLP-1 makes the process more approachable
Mortensen A, Aguilar F, Crebelli R, et al
Celebrate non-scale victories that reflect improved health and function, such as 12 : Feeling stronger in daily activities